Bayer has enlisted Blackford Analysis to develop a platform that will integrate artificial intelligence (AI) applications used in medical imaging.
Per a licensing and development deal, Blackford will develop the platform for Bayer, and Bayer will provide AI solutions of its own and from third parties. The companies announced the deal during the RSNA 2020 virtual conference being held this week.
The idea is to provide an integrated platform for AI applications that will work well within radiology department workflows and to connect imaging professionals to a virtual marketplace where they can access AI-related needs. An integrated platform will help radiologists meet the needs of an increasingly demanding work environment with better efficiency, according to the companies.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
